Related Experiment Video
Updated: Jul 16, 2025
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Palbociclib releases the latent differentiation capacity of neuroblastoma cells
Kirsty M Ferguson1, Sarah L Gillen1, Lewis Chaytor2
1Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Abstract:
Neuroblastoma is the most common extracranial solid tumor in infants, arising from developmentally stalled neural crest-derived cells. Driving tumor differentiation is a promising therapeutic approach for this devastating disease. Here, we show that the CDK4/6 inhibitor palbociclib not only inhibits proliferation but induces extensive neuronal differentiation of adrenergic neuroblastoma cells. Palbociclib-mediated differentiation is manifested by extensive phenotypic and transcriptional changes accompanied by the establishment of an epigenetic program driving expression of mature neuronal features. In vivo palbociclib significantly inhibits tumor growth in mouse neuroblastoma models. Furthermore, dual treatment with retinoic acid resets the oncogenic adrenergic core regulatory circuit of neuroblastoma cells, further suppresses proliferation, and can enhance differentiation, altering gene expression in ways that significantly correlate with improved patient survival. We therefore identify palbociclib as a therapeutic approach to dramatically enhance neuroblastoma differentiation efficacy that could be used in combination with retinoic acid to improve patient outcomes.
Insights
The CDK4/6 inhibitor palbociclib promotes neuronal differentiation in neuroblastoma cells. Combining palbociclib with retinoic acid may improve patient survival for this common infant cancer.
Area of Science:
- Oncology
- Developmental Biology
- Molecular Biology
Background:
- Neuroblastoma is a prevalent pediatric extracranial solid tumor originating from neural crest cells.
- Therapeutic strategies targeting tumor differentiation offer a promising avenue for treating neuroblastoma.
- Understanding the molecular mechanisms driving neuroblastoma development is crucial for effective treatment.
Purpose of the Study:
- To investigate the effect of the CDK4/6 inhibitor palbociclib on neuroblastoma differentiation.
- To explore the potential of palbociclib in combination with retinoic acid for neuroblastoma treatment.
- To elucidate the epigenetic and transcriptional changes associated with palbociclib-induced differentiation.
Main Methods:
- Treatment of adrenergic neuroblastoma cells with palbociclib.
- Assessment of phenotypic and transcriptional changes indicative of neuronal differentiation.
- In vivo studies using mouse models of neuroblastoma.
- Combination therapy studies with retinoic acid.
Main Results:
- Palbociclib inhibited proliferation and induced significant neuronal differentiation in neuroblastoma cells.
- Palbociclib treatment established an epigenetic program driving mature neuronal features.
- In vivo, palbociclib demonstrated significant inhibition of tumor growth.
- Combination therapy with retinoic acid reset oncogenic circuits, suppressed proliferation, and enhanced differentiation.
Conclusions:
- Palbociclib is identified as a potent agent for enhancing neuroblastoma differentiation.
- Combination therapy with palbociclib and retinoic acid shows potential for improving patient outcomes.
- Targeting differentiation pathways represents a viable therapeutic strategy for neuroblastoma.
More Related Videos
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
